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Several large-scale, multi-centered trials have demonstrated
that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, or “statins” as they are often
called, are effective in lowering total cholesterol and LDL-
cholesterol levels by up to 25% and 35%, respectively, and in
raising HDL-cholesterol levels by 5% to 10% (1,2). Statins
also reduce cardiovascular and overall mortality by up to
42% and 30%, respectively, in patients with significant risk
factors for ischemic heart disease, including a previous
diagnosis of angina pectoris or myocardial infarction with
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hypercholesterolemia (1). These beneficial effects extend to
patients with hypercholesterolemia but who have no history
of coronary artery disease (2). In this setting, a lowering of
total cholesterol by 20% and LDL-cholesterol by 26%
resulted in a relative risk reduction of coronary events by
31%, a reduction in cardiovascular deaths by 32% and a 22%
reduction in deaths from all causes over a follow-up period
of almost five years (2).
The effects of “statins” extend to patients with normal/
average cholesterol. It is clear that statins also have favor-
able clinical effects in patients with normal or average
cholesterol. The Long-Term Intervention with Pravastatin
in Ischemic Disease (LIPID) study demonstrated a striking
reduction in cardiovascular and all-cause mortality with
pravastatin in patients with an acute coronary syndrome,
either myocardial infarction or unstable angina, regardless of
pre-existing cholesterol levels (3). The reduction in cardio-
vascular events was greatest in patients whose baseline
cholesterol levels were elevated, however, all patients irre-
spective of the initial total cholesterol level benefited from
pravastatin (3). Similarly, in the Cholesterol and Recurrent
Events (CARE) study of patients with normal to average
serum cholesterol levels and a history of myocardial infarc-
tion, there was a significant reduction in cardiovascular
deaths, although not in overall mortality, with pravastatin
(4).
Statins are more effective in reducing cardiovascular
events than previously available lipid lowering agents.
Trials of cholesterol-lowering agents other than statins have
demonstrated lipid lowering from 6% reduction in total
cholesterol levels with clofibrate (in the Coronary Drug
Project) (5) to 14% reduction with colestipol (6) compared
with dietary treatment plus placebo. The clinical benefits
were also limited, with, for example, the Coronary Drug
Project demonstrating a 9% reduction in the combined
end-point of cardiovascular mortality and non-fatal myo-
cardial infarction (5). With colestipol, there was a 23%
reduction in the incidence of all cardiovascular events (6).
However, a feature of the majority of these trials before the
introduction of the statins is the absence of a reduction in
overall mortality. In some instances there was an increase in
deaths due to noncardiac causes. These findings extended to
trials of both primary and secondary prevention (7).
The apparent clinical superiority of the statins relative to
other cholesterol-lowering agents raises the possibility that
their beneficial effects reflect pharmacologic activities other
than cholesterol lowering. It is worth noting, however, that
the statins are far more effective in lowering total cholesterol
and LDL-cholesterol than previously studied agents (7).
Therefore, their superior effect may be related entirely to
their improved efficacy in lowering cholesterol. On the other
hand, angiographic studies demonstrate that significant
cholesterol reduction is associated with, at best, modest
regression of atherosclerosis and luminal narrowing (7).
Moreover, coronary thrombosis occurs in many cases on
lesions producing less than 50% luminal stenosis (8). To-
gether, these data raise the intriguing possibility that HMG
CoA reductase inhibitors reduce cardiovascular events and
death by mechanisms other than regression of coronary
atherosclerosis.
Biologic activity of HMG CoA reductase inhibitors.
The HMG CoA reductase inhibitors act primarily by
inhibiting the rate-limiting enzyme in cholesterol synthesis.
This results in up-regulation of hepatic LDL receptor
number and removal of total and LDL-cholesterol from
plasma. The HMG CoA reductase is also responsible for
the generation of isoprenoids, intermediates in the biosyn-
thetic pathway of cholesterol that modify the structure and
function of a variety of proteins (9). Statins have been
shown to induce vascular smooth muscle cell apoptosis
through inhibition of protein prenylation and thus may
inhibit vascular neointimal thickening (10). Statins also
reduce macrophage cholesterol synthesis and reduce mac-
rophage foam cell formation, thereby stabilizing the athero-
sclerotic plaque (9).
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Antiplatelet effects. Lam et al. have provided direct evi-
dence for an antithrombotic effect of a statin using an
experimental model of coronary thrombosis (11). Davi et al.
have shown that hypercholesterolemia is associated with
platelet activation, in humans, detected as an increase in
formation of thromboxane A2, the principle prostaglandin
generated by platelets and a potent platelet activator (12,13).
There is also evidence that these patients have enhanced
platelet aggregation. Treatment with simvastatin at a dose
that reduced LDL-cholesterol by 30% to 40% in patients
with hypercholesterolemia resulted in normalization of al-
tered platelet aggregation ex vivo and a 50% reduction in
thromboxane metabolite excretion when compared with
placebo (13).
It is unlikely that a reduction in thromboxane A2 per se
explains the antithrombotic effects as the clinical benefits of
statins are evident even in patients receiving aspirin (which
comprised .80% of patients in the LIPID trial) (4).
However, several studies suggest that oxidized LDL can
activate platelets directly (14). The antiplatelet activity may
also involve reduction in the platelet membrane cholesterol
content (15). Recently, a series of isomers of prostaglandins
termed isoprostanes have been found in atherosclerotic
tissue (16) and oxidized LDL. These are generated nonen-
zymatically by free radical attack of arachidonic acid in cell
membranes and so are insensitive to aspirin (17). Several of
these have biologic activity, including 8-epi-PGF2a, which
is a potent platelet activator and vascular smooth muscle cell
mitogen. Isoprostane formation is increased in patients with
atherosclerosis, possibly reflecting an increase in oxidant
tone (18). The increase is normalized by treatment with a
statin and this in turn may modulate platelet activity.
The HMG CoA reductase inhibitors exert several other
effects in patients with atherosclerotic disease and hyper-
cholesterolemia that may indirectly modify platelet activity.
These include favorable modification of endothelial func-
tion, stabilization of atherosclerotic plaque by reducing lipid
content and lipid-laden macrophages and increasing the
relative volume of collagen and smooth muscle cells within
the plaque (14). This last effect would strengthen the fibrous
element of plaque, reducing the risk of plaque rupture,
thrombus formation and acute coronary events.
Effects on coagulation? In this issue of the Journal, two
articles deal with the potential effects of statins on thrombin
generation (19,20). Szczeklik et al. (19) determined the
levels of prothrombin fragment 1.2 (F1.2) and fibrinopep-
tide (FP) A, thrombin cleavage products of prothrombin
and fibrinogen, respectively, in patients with a total serum
cholesterol of .6.5 mmol/liter (19). Patients who failed to
respond to simvastatin with a substantial reduction in
cholesterol were excluded from the analysis. There was a
profound fall in total serum cholesterol in the analyzed
patients, with the average pre-treatment cholesterol of 8.0
mmol/liter decreasing to 5.4 mmol/liter on simvastatin. The
generation of thrombin cleavage peptides in bleeding time
blood (aspirated from the site of a skin incision) was
inhibited by simvastatin. Aspirin had a similar effect, and
there was no further reduction in thrombin cleavage pep-
tides by the addition of simvastatin to aspirin.
These findings suggest that the reduction in thrombin
generation by simvastatin was secondary to an antiplatelet
effect and specifically inhibition of thromboxane A2, the
principle biologic effect of aspirin. Platelets provide a surface
for the assembly of enzyme complexes required for throm-
bin activation. Interestingly, enhanced platelet dependent
thrombin generation has been reported in patients with
hypercholesterolemia and to normalize on treatment with
pravastatin (21). Although Szczeklik could not demonstrate
a reduction in plasma levels of FPA or F1.2, this is not
surprising because levels of these peptides are usually normal
in the absence of an acute coronary syndrome (22).
Likewise, in a second article in this issue of the Journal,
Dangas et al. show that plasma concentrations of FPA and
F1.2 are unaffected by pravastatin in patients with hyper-
cholesterolemia (20). However, pravastatin reduced throm-
bus generation in an ex vivo model where the patient’s blood
was passed through a perfusion system. The reduction in
thrombosis was attenuated in patients on aspirin, again
suggesting that aspirin and the statin operate through the
same pathway. Thus, in both studies, a statin was effective
when thrombosis was provoked and in both studies the
effect was attenuated by aspirin.
In conclusion, these studies suggest that statins exert
antithrombotic effects largely as a result of an antiplatelet
activity. The antithrombotic effect was attenuated by aspi-
rin, consistent with the findings of Davi et al., that statins
suppress the abnormal generation of thromboxane seen in
subjects with hypercholesterolemia. However, the cardio-
vascular benefits reported with statins are in populations
where a high percentage of subjects are on aspirin, and so it
is unlikely that this antithrombotic activity contributes to
the clinical benefit seen. It is also not clear whether these
models reported by Szczeklik and Dangas truly mimic
vascular thrombosis. And to complicate matters further,
Dangas reports that during the treatment period there was
an increase in fibrinogen, a known risk factor for coronary
thrombosis (23). But that’s another story.
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